Dr. Reddy's Laboratories Limited has informed the Exchange that Record date for the purpose of Dividend is 10-Jul-2025.
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty 100 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Reddy's Laboratories announced audited consolidated results for Q4 and FY25. Q4 FY25 revenue grew 20% YoY to Rs. 85,060 million, while profit after tax (attributable to equity holders) rose 22% YoY to Rs. 15,939 million. For full year FY25, revenue increased 17% YoY to Rs. 325,535 million and PAT rose 2% YoY to Rs. 56,544 million, supported by the recently acquired Haleon NRT consumer healthcare business and steady growth in Global Generics. The Board recommended a final dividend of Rs. 8 per equity share (face value Rs. 1) for FY25, with the record date fixed as July 10, 2025 and the 41st AGM scheduled for July 24, 2025. The Board also re-appointed G V Prasad as Co-Chairman & Managing Director for 5 years from January 30, 2026, and appointed Makarand M Joshi & Co. as Secretarial Auditors for a 5-year term.
Strong Q4 performance with 20% revenue growth reflects robust business momentum, aided by the NRT acquisition, which should be positive for investor sentiment. Shareholders holding shares as of July 10, 2025 will be eligible for the Rs. 8 final dividend, providing direct cash return alongside long-term growth prospects.